Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568

Positive Phase 2 Data:
Neurocrine Biosciences reported positive Phase 2 data for NBI-1117568, a muscarinic M4 selective acetylcholine receptor agonist, in the treatment of schizophrenia.

Phase 3 Advancement:
The successful Phase 2 results support the advancement of NBI-1117568 to Phase 3 trials in early 2025.

Efficacy and Safety:
The once-daily 20 mg dose of NBI-1117568 demonstrated a statistically significant 7.5-point improvement in the PANSS total score compared to placebo at Week 6, with an 18.2-point PANSS total score improvement from baseline.

Competition:
Neurocrine is competing with Bristol Myers Squibb and AbbVie in the development of schizophrenia treatments, with KarXT being a notable competitor.

Clinical Studies:
Neurocrine is conducting several clinical studies, including the Journey™ Study for valbenazine in schizophrenia and the SAVITRI™ study for NBI-1065845 in major depressive disorder.